University Hospital Erlangen

This phase 3 trial tests a personalized vaccine made from a patient's own immune cells and tumor RNA to prevent uveal melanoma from coming back after surgery. The study includes 200 people with a high-risk genetic type (monosomy 3) and no signs of spread. Half receive the vaccine…